Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine
Identifieur interne : 006295 ( Ncbi/Checkpoint ); précédent : 006294; suivant : 006296Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine
Auteurs : Lotte M. G. SteutenSource :
- OMICS : a Journal of Integrative Biology [ 1536-2310 ] ; 2016.
Abstract
Health technology assessment (HTA) is a crucial science that influences the responsible and evidence-based transition of new discoveries from laboratory to applications in the clinic and society. HTA has recently moved “upstream” so as to assess technologies from their onset at their discovery, design, or planning phase. Biomarker research is relatively recent in oral health, but growing rapidly with investments made to advance dentistry and oral health and importantly, to build effective bridges between oral health and systems medicine since what happens in oral health affects systems pathophysiology, and vice versa. This article offers a synthesis of the latest trends and approaches in early phase HTA, with a view to near future applications in oral health, systems medicine, and biomarker-guided precision medicine. In brief, this review underscores that demonstrating health outcomes of biomarkers and next-generation diagnostics is particularly challenging because they do not always influence long-term outcomes directly, but rather impact subsequent care processes. Biomarker testing costs are typically less of a barrier to uptake in practice than the biomarker's impact on longer term health outcomes. As a single biomarker or next-generation diagnostic in oral health can inform decisions about numerous downstream diagnosis-treatment combinations, early stage “upstream” HTA is crucial in prioritizing the most valuable diagnostic applications to pursue first. For the vast array of oral health biomarkers currently developed, early HTA is necessary to timely and iteratively assess their comparative effectiveness and anticipate the inevitable questions about value for money from regulators and payers.
Url:
DOI: 10.1089/omi.2015.0174
PubMed: 26760958
PubMed Central: 4739424
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000784
- to stream Pmc, to step Curation: 000784
- to stream Pmc, to step Checkpoint: 000747
- to stream Ncbi, to step Merge: 006295
- to stream Ncbi, to step Curation: 006295
Links to Exploration step
PMC:4739424Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine</title>
<author><name sortKey="Steuten, Lotte M G" sort="Steuten, Lotte M G" uniqKey="Steuten L" first="Lotte M. G." last="Steuten">Lotte M. G. Steuten</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">26760958</idno>
<idno type="pmc">4739424</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739424</idno>
<idno type="RBID">PMC:4739424</idno>
<idno type="doi">10.1089/omi.2015.0174</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000784</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000784</idno>
<idno type="wicri:Area/Pmc/Curation">000784</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000784</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000747</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000747</idno>
<idno type="wicri:Area/Ncbi/Merge">006295</idno>
<idno type="wicri:Area/Ncbi/Curation">006295</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">006295</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine</title>
<author><name sortKey="Steuten, Lotte M G" sort="Steuten, Lotte M G" uniqKey="Steuten L" first="Lotte M. G." last="Steuten">Lotte M. G. Steuten</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">OMICS : a Journal of Integrative Biology</title>
<idno type="ISSN">1536-2310</idno>
<idno type="eISSN">1557-8100</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Abstract</title>
<p>Health technology assessment (HTA) is a crucial science that influences the responsible and evidence-based transition of new discoveries from laboratory to applications in the clinic and society. HTA has recently moved “upstream” so as to assess technologies from their onset at their discovery, design, or planning phase. Biomarker research is relatively recent in oral health, but growing rapidly with investments made to advance dentistry and oral health and importantly, to build effective bridges between oral health and systems medicine since what happens in oral health affects systems pathophysiology, and vice versa. This article offers a synthesis of the latest trends and approaches in early phase HTA, with a view to near future applications in oral health, systems medicine, and biomarker-guided precision medicine. In brief, this review underscores that demonstrating health outcomes of biomarkers and next-generation diagnostics is particularly challenging because they do not always influence long-term outcomes directly, but rather impact subsequent care processes. Biomarker testing costs are typically less of a barrier to uptake in practice than the biomarker's impact on longer term health outcomes. As a single biomarker or next-generation diagnostic in oral health can inform decisions about numerous downstream diagnosis-treatment combinations, early stage “upstream” HTA is crucial in prioritizing the most valuable diagnostic applications to pursue first. For the vast array of oral health biomarkers currently developed, early HTA is necessary to timely and iteratively assess their comparative effectiveness and anticipate the inevitable questions about value for money from regulators and payers.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Steuten, Lotte M G" sort="Steuten, Lotte M G" uniqKey="Steuten L" first="Lotte M. G." last="Steuten">Lotte M. G. Steuten</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006295 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 006295 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= EdenteV2 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= PMC:4739424 |texte= Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:26760958" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a EdenteV2
![]() | This area was generated with Dilib version V0.6.32. | ![]() |